IN THESE PAGES
12 good Vibrations
14 Where the Wild Things are
16 Kicking Carbon
Long a high-profit business,
the pharmaceutical industry has recently
shown some troubling symptoms.
Companies invest tons of money,
as well as years of research, trying to
develop game-changing blockbuster
drugs that, if successful, will deliver
phenomenal profits. But if they fail,
companies are left hemorrhaging mas-
sive amounts of time and money.
the unwieldy model is sparking
what John C. Lechleiter, phD, chair-
man, president and CEo of pharma-
ceutical giant Eli Lilly and Co., called
an “innovation crisis.” Writing in The
Wall Street Journal in July, he noted
that although research and develop-
ment (r&D) costs continue to rise,
fewer new drugs are gaining regulatory
approval in the United States.
one vaccination against stagnation
could be open source. first popular-
ized in software development, it lifted
the veil on coding, enabling multiple
developers to build off each other’s
ideas. a similar approach could let
drug companies break out of the devel-
opment doldrums—and help them
avoid repeating mistakes.
“for every step in the drug-development process, knowing what
doesn’t work is interesting, especially
when you are working with limited
funds,” says James McKerrow, phD,
MD, director of the Sandler Center for
Submit news to firstname.lastname@example.org. All monetary figures are in U. S. dollars unless otherwise noted.
ILLUSTRATION BY KEITH NEGLEY
10 PM NETWORK MAY 2008 WWW.PMI.ORG
SEE THE LATEST NEWS about project, program and
portfolio management online at www.pmi.org/PMport.